Cantor Fitzgerald & ADMA Biologics
2 shared events · Importance 3 · Last updated Jul 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Cantor Fitzgerald: Cantor Fitzgerald downgraded ADMA Biologics' stock, citing disappointment with the company's response to the Culper Research report, further contributing to the stock's decline.
ADMA Biologics: ADMA Biologics is the primary subject of the class action lawsuits and investigations due to allegations of channel stuffing, undisclosed related-party transactions, and misleading revenue growth, which caused its stock price to decline significantly.
Apr 01, 2026 · 301 articles
Regulatory
Cantor Fitzgerald: Cantor Fitzgerald downgraded ADMA Biologics stock from Overweight to Neutral following the Culper Research report.
ADMA Biologics: ADMA Biologics is the defendant in the securities class action, accused of making false and misleading statements. The lawsuit and allegations have led to a significant drop in its stock price and could result in substantial financial penalties and reputational harm.
Jun 14, 2026 · 294 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Cantor Fitzgerald and ADMA Biologics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard